Related Experiment Video

Updated: Jun 9, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin and other biguanides in oncology: advancing the research agenda

Michael Pollak1

  • 13755 Cote-Ste.-Catherine, Montreal, Quebec, Canada H3T 1E2. michael.pollak@mcgill.ca

Cancer Prevention Research (Philadelphia, Pa.)
|September 3, 2010
PubMed

Insights

Metformin may reduce cancer burden in diabetics, with lab studies supporting its use in cancer prevention and treatment. Further research is needed to confirm these findings and explore broader applications.

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Retrospective studies suggest metformin use in diabetics is associated with reduced cancer burden.
  • The exact mechanisms behind this observation (chemoprevention vs. effect on transformed cells) remain unclear.
  • Relevance of these findings to non-diabetic populations requires investigation.

Purpose of the Study:

  • To explore the potential of metformin and other biguanides in cancer chemoprevention and treatment.
  • To address knowledge gaps in the mechanisms of action of biguanides.
  • To inform the design of future clinical trials for biguanide-based cancer therapies.

Main Methods:

  • Review of retrospective studies on metformin and cancer in diabetic patients.
  • Examination of laboratory models investigating biguanide activity in cancer.
  • Analysis of existing research on biguanide mechanisms of action.

Main Results:

  • Laboratory models provide strong evidence for biguanide efficacy in cancer treatment and prevention.
  • Significant complexity in biguanide mechanisms of action has been identified.
  • Gaps in knowledge regarding biguanide action necessitate further research.

Conclusions:

  • Metformin and biguanides show promise for cancer prevention and treatment.
  • Further investigation into biguanide mechanisms is crucial for clinical trial design.
  • Biguanides may offer new therapeutic indications for various common cancers.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...